B-SPECIFIC 4 PATIENTS: STUDY OF PEDIATRIC EFFICACY AND SAFETY WITH FIRST-LINE USE OF CANAKINUMAB: AN OPEN-LABEL CANAKINUMAB (ACZ885) DOSE REDUCTION OR DOSE INTERVAL PROLONGATION EFFICACY AND SAFETY STUDY IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS

Registry ID

CACZ885G2306

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

NOVARTIS PHARMACEUTICALS CANADA INC

Start date

2015-05-05

Last update

2014-10-01

Conditions

• JUVENILE IDIOPATHIC ARTHRITIS (JIA)

Related clinical trials

• AN OPEN-LABEL MULTIPLE-DOSE STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF UPADACITINIB IN PEDIATRIC SUBJECTS WITH POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS
• AN OPEN-LABEL, SEQUENTIAL, ASCENDING, REPEATED DOSE-FINDING STUDY OF SARILUMAB, ADMINISTERED WITH SUBCUTANEOUS (SC) INJECTION, IN CHILDREN AND ADOLESCENTS, AGED 1 TO 17 YEARS, WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA), FOLLOWED BY AN EXTENSION PHASE
• A LONG TERM, OPEN LABEL FOLLOW UP STUDY OF CP 690,550 FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA)
• A MULTICENTER, OPEN-LABEL TRIAL OF INTRAVENOUS GOLIMUMAB A HUMAN ANTI-TNFA ANTIBODY, IN PEDIATRIC SUBJECTS WITH ACTIVE POLYARTICULAR COURSE JUVENILE IDIOPATHIS ARTHRITIS DESPITE METHOTREXATE THERAPY
• "A PHASE IB, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMIS, AND SAFETY OF TOCILIZUMAB FOLLOWING SUBCUTANEOUS ADMINISTRATION TO PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS."
• "A PHASE IBM OPEN-LABEL, MULTI-CENTER STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF TOCILIZUMAB FOLLOWING SUBCUTANEOUS ADMINISTRATION TO PATIENTS WITH POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS."

View on source registry